Jacobio Pharmaceuticals Group Co., Ltd. reported to the Hong Kong Stock Exchange that it repurchased 82,800 ordinary shares on 18 May 2026. The shares were bought on-market at prices ranging between HK$5.55 and HK$5.56, representing a volume-weighted average of HK$5.56 per share and an aggregate consideration of HK$0.46 million.

Following the transaction, Jacobio’s outstanding share count (excluding treasury shares) decreased by 0.01055% to 784.61 million, while treasury shares increased to 7.15 million. Total issued shares remained unchanged at 791.76 million because the repurchased shares were retained in treasury rather than cancelled.

The buyback forms part of a repurchase mandate approved on 10 June 2025, which authorises the company to buy back up to 78.87 million shares. Cumulatively, Jacobio has now repurchased 4.13 million shares under this mandate, equivalent to 0.52% of the company’s issued share capital at the time the authority was granted. A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 17 June 2026, in line with Hong Kong listing rules.